Equianalgesia, opioid switch and opioid association in different clinical settings: a narrative review.
暂无分享,去创建一个
F. Marinangeli | F. De Iaco | P. Sansone | G. Mannaioni | G. Finco | S. Sartori | S. Serra | E. Gandolfo
[1] H. Jones,et al. Trends in Opioid and Psychotropic Prescription in Pregnancy in the United States From 2001 to 2015 in a Privately Insured Population , 2020, Annals of Internal Medicine.
[2] J. Reimer,et al. Switching opioid-dependent patients in substitution treatment from racemic methadone, levomethadone and buprenorphine to slow-release oral morphine: Analysis of the switching process in routine care. , 2020, Journal of pharmacological sciences.
[3] A. Fabbri,et al. Role of Inhaled Methoxyflurane in the Management of Acute Trauma Pain , 2020, Journal of pain research.
[4] R. Rauck,et al. Buprenorphine buccal film for chronic pain management. , 2020, Pain management.
[5] J. Fudin,et al. A Narrative Pharmacological Review of Buprenorphine: A Unique Opioid for the Treatment of Chronic Pain , 2020, Pain and Therapy.
[6] Chelsea E. Hawley,et al. Opioid Management in Older Adults with Chronic Kidney Disease: A Review. , 2019, The American journal of medicine.
[7] E. Bruera,et al. Safe and Appropriate Use of Methadone in Hospice and Palliative Care: Expert Consensus White Paper. , 2019, Journal of pain and symptom management.
[8] S. Laurent,et al. Practical management of opioid rotation and equianalgesia , 2018, Journal of pain research.
[9] P. Hoskin,et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] A. Caraceni,et al. Factors Influencing the Clinical Presentation of Breakthrough Pain in Cancer Patients , 2018, Cancers.
[11] F. Heid,et al. Opioid Rotation in Cancer Pain Treatment. , 2018, Deutsches Arzteblatt international.
[12] A. Lembke,et al. Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period , 2018, Pain medicine.
[13] M. Rech,et al. When to Pick the Nose: Out‐of‐Hospital and Emergency Department Intranasal Administration of Medications , 2017, Annals of emergency medicine.
[14] Vittal R. Nagar,et al. Opioid Use in Chronic Pain Patients with Chronic Kidney Disease: A Systematic Review , 2017, Pain medicine.
[15] K. Weant,et al. Review of Intranasally Administered Medications for Use in the Emergency Department. , 2017, The Journal of emergency medicine.
[16] R. Raffa,et al. Cebranopadol: novel dual opioid/NOP receptor agonist analgesic , 2017, Journal of clinical pharmacy and therapeutics.
[17] E. Wachman,et al. Comparison of Neonatal Abstinence Syndrome Manifestations in Preterm Versus Term Opioid-Exposed Infants , 2016, Advances in neonatal care : official journal of the National Association of Neonatal Nurses.
[18] Elizabeth Chuang,et al. Pain management strategies for patients on methadone maintenance therapy: a systematic review of the literature , 2016, BMJ Supportive & Palliative Care.
[19] O. Olivieri,et al. Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso‐Occlusive Crisis in Sickle Cell Disease , 2016, Pain practice : the official journal of World Institute of Pain.
[20] Manar H. Jbara,et al. A new mathematical approach to methadone conversion , 2016, Journal of pharmacology & pharmacotherapeutics.
[21] E. Bruera,et al. Opioid switching in cancer pain: From the beginning to nowadays. , 2016, Critical reviews in oncology/hematology.
[22] A. Finn,et al. Evaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal Buprenorphine , 2016, Pain medicine.
[23] S. Mercadante. Opioid metabolism and clinical aspects. , 2015, European journal of pharmacology.
[24] M. Corrigan,et al. Safety and efficacy of intranasally administered medications in the emergency department and prehospital settings. , 2015, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[25] S. Mclean,et al. Methods of Rotation From Another Strong Opioid to Methadone for the Management of Cancer Pain: A Systematic Review of the Available Evidence. , 2015, Journal of pain and symptom management.
[26] K. Kulig,et al. Cebranopadol: a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors , 2015, Expert opinion on investigational drugs.
[27] F. Paoletti,et al. Italian Intersociety Recommendations on pain management in the emergency setting (SIAARTI, SIMEU, SIS 118, AISD, SIARED, SICUT, IRC). , 2015, Minerva anestesiologica.
[28] H. Sachs. The Transfer of Drugs and Therapeutics Into Human Breast Milk: An Update on Selected Topics , 2013, Pediatrics.
[29] P. Schofield,et al. Guidance on the management of pain in older people. , 2013, Age and ageing.
[30] G. Badger,et al. Differences in the profile of neonatal abstinence syndrome signs in methadone- versus buprenorphine-exposed neonates. , 2012, Addiction.
[31] P. Stone,et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. , 2012, The Lancet. Oncology.
[32] Y. Daali,et al. Analgesics in Patients with Hepatic Impairment , 2012, Drugs.
[33] A. Somogyi,et al. Acute Pain Management in Opioid-Tolerant Patients: A Growing Challenge , 2011, Anaesthesia and intensive care.
[34] Albert Dahan,et al. Current Knowledge of Buprenorphine and Its Unique Pharmacological Profile , 2010, Pain practice : the official journal of World Institute of Pain.
[35] F. Roila,et al. Management of cancer pain: ESMO Clinical Practice Guidelines. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[36] G. Hans,et al. Opioid Rotation in the Management of Chronic Pain: Where Is the Evidence? , 2010, Pain practice : the official journal of World Institute of Pain.
[37] A. Falcão,et al. Intranasal drug delivery: how, why and what for? , 2009, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[38] J. Raeder,et al. A Comparison of Intravenous Oxycodone and Intravenous Morphine in Patient-Controlled Postoperative Analgesia After Laparoscopic Hysterectomy , 2009, Anesthesia and analgesia.
[39] R. Portenoy,et al. Establishing "best practices" for opioid rotation: conclusions of an expert panel. , 2009, Journal of pain and symptom management.
[40] S. Mercadante,et al. Equipotent doses to switch from high doses of opioids to transdermal buprenorphine , 2009, Supportive Care in Cancer.
[41] S. Mercadante,et al. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. , 2009, Journal of pain and symptom management.
[42] R. Cohen. Fentanyl Transdermal Analgesia During Pregnancy and Lactation , 2009, Journal of human lactation : official journal of International Lactation Consultant Association.
[43] L. Ståhle,et al. Transfer of Buprenorphine Into Breast Milk and Calculation of Infant Drug Dose , 2009, Journal of human lactation : official journal of International Lactation Consultant Association.
[44] R. Upton,et al. Pharmacokinetics and Pharmacodynamics of Intranasal Versus Intravenous Fentanyl in Patients with Pain after Oral Surgery , 2008, The Annals of pharmacotherapy.
[45] A. Williamson,et al. Management of acute pain in methadone maintenance therapy in-patients. , 2008, Drug and alcohol review.
[46] A. Dahan,et al. Opioids and the Management of Chronic Severe Pain in the Elderly: Consensus Statement of an International Expert Panel with Focus on the Six Clinically Most Often Used World Health Organization step III Opioids (Buprenorphine, Fentanyl, Hydromorphone, Methadone, Morphine, Oxycodone) , 2008, Pain practice : the official journal of World Institute of Pain.
[47] L. Illum,et al. Intranasal delivery: physicochemical and therapeutic aspects. , 2007, International journal of pharmaceutics.
[48] R. Walsky,et al. Evaluation of 227 Drugs for In Vitro Inhibition of Cytochrome P450 2B6 , 2006, Journal of clinical pharmacology.
[49] J. Vender,et al. Pharmacokinetics of midazolam, propofol, and fentanyl transfer to human breast milk , 2006, Clinical pharmacology and therapeutics.
[50] E. Bruera,et al. Opioid switching: a systematic and critical review. , 2006, Cancer treatment reviews.
[51] M. Danhof,et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. , 2006, British journal of anaesthesia.
[52] D. Alford,et al. Acute Pain Management for Patients Receiving Maintenance Methadone or Buprenorphine Therapy , 2006, Annals of Internal Medicine.
[53] Alexander Lachmann,et al. The effects of racemic D,L-methadone and L-methadone in substituted patients--a randomized controlled study. , 2005, Drug and alcohol dependence.
[54] S. Mercadante,et al. Addition of a second opioid may improve opioid response in cancer pain: preliminary data , 2004, Supportive Care in Cancer.
[55] C. Yost,et al. Functional Inhibition by Methadone of N-Methyl-d-Aspartate Receptors Expressed in Xenopus Oocytes: Stereospecific and Subunit Effects , 2004, Anesthesia and analgesia.
[56] G. Lauretti,et al. Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients , 2003, British Journal of Cancer.
[57] V. Kouloulias,et al. Long‐term cancer pain management in morphine pre‐treated and opioid naive patients with transdermal fentanyl , 2003, International journal of cancer.
[58] Hiroshi Baba,et al. The Role of N-Methyl-d-Aspartate (NMDA) Receptors in Pain: A Review , 2003, Anesthesia and analgesia.
[59] W. Ling,et al. The Clinical Opiate Withdrawal Scale (COWS) , 2003, Journal of psychoactive drugs.
[60] C. Sessler,et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. , 2002, American journal of respiratory and critical care medicine.
[61] P. McNamara. Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care , 2002, Palliative medicine.
[62] A. Vigano,et al. Equianalgesic dose ratios for opioids. a critical review and proposals for long-term dosing. , 2001, Journal of pain and symptom management.
[63] F. Fulfaro,et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] K. Turner,et al. The rediscovery of methadone for cancer pain management , 2001, The Medical journal of Australia.
[65] E. Bruera,et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] E. Kalso,et al. Controlled-release oxycodone and morphine in cancer related pain , 1997, Pain.
[67] N. Hagen,et al. Comparative clinical efficacy and safety of a novel controlled‐release oxycodone formulation and controlled‐release hydromorphone in the treatment of cancer pain , 1997, Cancer.
[68] W. Paton,et al. The action of morphine and related substances on contraction and on acetylcholine output of coaxially stimulated guinea‐pig ileum , 1997, British journal of pharmacology.
[69] M. Tryba,et al. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain , 1996, Pain.
[70] E. Kalso,et al. Morphine and oxycodone hydrochloride in the management of cancer pain , 1990, Clinical pharmacology and therapeutics.
[71] R. Houde,et al. A dinical eomparison of the analgesie effects of methadone and morphine administered intramuseularly, and oforally and parenterally administered methadone , 1967, Clinical pharmacology and therapeutics.
[72] Sarah Reece-Stremtan,et al. ABM Clinical Protocol #15: Analgesia and Anesthesia for the Breastfeeding Mother, Revised 2017. , 2017, Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine.
[73] H. Ding,et al. Central N/OFQ-NOP Receptor System in Pain Modulation. , 2016, Advances in pharmacology.
[74] N. Magrini,et al. WHO guidelines on the pharmacological treatment of persisting pain in children with medical illnesses , 2012 .
[75] S. Schug,et al. Formulations of Fentanyl for the Management of Pain , 2012, Drugs.
[76] J. Lötsch,et al. Pharmacokinetics of Non-Intravenous Formulations of Fentanyl , 2012, Clinical Pharmacokinetics.
[77] Takako Miyoshi,et al. Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models. , 2009, Journal of pharmacological sciences.
[78] R. Portenoy,et al. Opioid rotation: the science and the limitations of the equianalgesic dose table. , 2009, Journal of pain and symptom management.
[79] S. Datta,et al. Opioid pharmacology. , 2008, Pain physician.
[80] M. Moretti. Drugs during Pregnancy and Lactation, 2nd edition , 2008 .
[81] M. Fallon. Principles of opioid titration , 2007 .
[82] R. D. du Bois,et al. No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. , 2006, Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.
[83] C. Quigley,et al. Opioid switching to improve pain relief and drug tolerability. , 2004, The Cochrane database of systematic reviews.
[84] T. Buclin,et al. Interindividual Variability of the Clinical Pharmacokinetics of Methadone , 2002, Clinical pharmacokinetics.
[85] A. Miller,et al. A RANDOMISED CROSSOVER COMPARISON OF CONTROLLED RELEASE HYDROMORPHONE TABLETS WITH CONTROLLED RELEASE MORPHINE TABLETS IN PATIENTS WITH CANCER PAIN , 1999 .